Guess Who’s Coming to Inspect R&D?
September 01, 2023
Columns: Focus on Quality
The publication of a new FDA compliance policy for pre-approval inspections (PAIs) introduces a new objective to inspect research and development in
pharmaceutical development. We explore how this could influence the PAI process now.